Back to Market返回行情

MLAB Mesa Laboratories, Inc.

USTechnology
$95.61+0.23%ClosedMarket Cap: $528.2M

As of 2026-07-10 16:00

Why MLAB matters now

Mesa Laboratories, Inc. (MLAB) is a US stock in Technology. The latest InvestLog snapshot shows $95.61 with +0.23% on the session and $528.2M in market capitalization; recent performance reads 1-month -4.74% and YTD +21.15%.

The latest financial table shown here is Q4 2026, with revenue of $63.7M, net income of $-4.1M, and EPS of $-0.75. Investors can compare that operating picture with valuation signals such as P/E 139.32 and FCF yield 8.2%.

The latest indexable market news headline is "MESA LABS DECLARES QUARTERLY DIVIDEND" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Hold with a median target of $94.00; recent insider activity includes Sakys John filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

139.32

PEG

1.37

P/B

2.83

P/S

2.11

EV/EBITDA

15.38

DCF Value

$20.76

FCF Yield

8.2%

Div Yield

0.7%

Margins & Returns

Gross Margin

63.5%

Operating Margin

7.4%

Net Margin

2.7%

ROE

3.7%

ROA

1.6%

ROIC

2.8%

Financials

PeriodRevenueNet IncomeEPS
Q4 2026$63.7M$-4.1M$-0.75
FY 2026$249.1M$6.7M$1.21
Q3 2026$65.1M$3.6M$0.65
Q2 2026$60.7M$2.5M$0.45

Analyst Ratings

Consensus

Hold

Target (Consensus)

$94.00

Target (Median)

$94.00

Target Range

$94.00 - $94.00

Strong Buy: 0Buy: 1Hold: 2Sell: 0Strong Sell: 0
Wells FargoEqual Weight
2026-02-04
Wells FargoEqual Weight
2025-12-15
Wells FargoEqual Weight
2025-08-08

Trading Activity

Insider Trades

Sakys Johnofficer: CFO
Sell2026-06-17
Crennen Lyndsey Elizabethofficer: CAO
Sell2026-06-17
Archbold Brian Davidofficer: SVP Operations
Sell2026-06-17
Crennen Lyndsey Elizabethofficer: Chief Accounting Officer
Sell2026-06-16
Crennen Lyndsey Elizabethofficer: Chief Accounting Officer
Sell2026-06-16

Company Info

Sector

Technology

Industry

Hardware, Equipment & Parts

Country

US

Exchange

Beta

0.93

Mesa Laboratories, Inc. (MLAB) operates as a global enterprise focused on the creation, production, and distribution of essential life science tools, quality assurance products, and specialized services. Its market reach extends across the United States, Europe, the Asia Pacific region, and other international territories. The company's operations are organized into four distinct segments: 1. Sterilization and Disinfection Control: This division manufactures and supplies biological, chemical, and cleaning indicators designed to verify the effectiveness of sterilization and disinfection protocols. These products are vital for industries such as hospitals, dental practices, medical device manufacturing, and pharmaceuticals. Additionally, it offers specialized testing and laboratory services, primarily catering to the dental sector. 2. Biopharmaceutical Development: This segment is dedicated to developing, producing, and marketing automated solutions for protein analysis, including immunoassays, and comprehensive peptide synthesis technologies. Its portfolio encompasses analysis equipment, CDs, kits, and buffers for protein analysis, alongside peptide synthesizers that automate the chemical creation of peptides. These synthesized peptides are utilized in the development of therapeutic agents, biomaterials, cosmetic products, and general scientific research. 3. Calibration Solutions: This division designs, manufactures, and commercializes quality control and calibration instruments. These products are crucial for accurately measuring and calibrating parameters such as temperature, pressure, pH, and humidity, ensuring health and safety standards. Their applications span hospitals, medical device and pharmaceutical manufacturing facilities, and various laboratory and healthcare environments. Key offerings include continuous monitoring systems, dialysate meters and their consumables, data logging devices, gas flow calibration and air sampling equipment, and torque testing systems. 4. Clinical Genomics: This segment innovates, produces, and provides advanced genetic analysis tools. A prominent offering is the MassARRAY system, complemented by essential consumables like chips, panels, and chemical reagent solutions. These tools enable clinical laboratories to perform genomic testing across several therapeutic areas, including newborn screening, pharmacogenomics, and oncology. Mesa Laboratories, Inc. was established in 1982 and is headquartered in Lakewood, Colorado.